Advertisement

Journal of Diabetes & Metabolic Disorders

, Volume 18, Issue 1, pp 133–143 | Cite as

In vivo studies demonstrate that endothelin-1 traps are a potential therapy for type I diabetes

  • Arjun JainEmail author
  • Vidhi Mehrotra
  • Ira Jha
  • Ashok Jain
Research Article

Abstract

Background

Type 1 diabetes is a serious, lifelong condition where the body’s blood glucose level increases because of the body’s inability to make insulin. An important consequence of this is the increased expression of extracellular matrix proteins, such as fibronectin and collagen 4α1, in key tissues and organs like the heart and kidneys. Diabetes is also associated with increased plasma levels of the vasoactive peptide endothelin (ET)-1. This further aggravates the expression of the ECM proteins. There are also important consequences of increased glucose and ET-1 levels in diabetes on the heart, termed diabetic cardiomyopathy.

Methods

We have previously reported the development of ET-traps, which potently and significantly reduce pathological levels of ET-1. In this study, we tested the in vivo therapeutic potential of ET-traps for type 1 diabetes using the B6 mouse model.

Results

Following subcutaneous administration of ET-traps 3 times a week, over a 2 month period, the 500 nM dose of ET-traps gave a significant reduction in collagen 4α1 expression in the heart and kidney, returning it back to control, non-diabetic levels at both the mRNA and protein levels. The expression of fibronectin mRNA is also returned to control levels with the 500 nM dose of ET-traps. The efficacy of ET-traps for type 1 diabetes was further evinced by immunohistochemistry data, echocardiography studies (measuring left ventricular systolic function and diastolic dysfunction) and a measure of urine creatinine and albumin levels. In all analyses, the 500 nM dose of ET-traps returns the different measures to control, non-diabetic levels.

Conclusion

Data from this study show that in a mouse model ET-traps have a potent and significant therapeutic effect on diabetes disease pathology. Future studies could further evaluate the use of ET-traps as a therapy for diabetes, including taking them through clinical trials.

Keywords

DM, Diabetes mellitus ECM, Extracellular matrix ET-1, Endothelin-1 ETtr, Endothelin-1 traps FFP, Fc-fusion protein 

Abbreviations

ALT

Alanine aminotransferase

AST

Aspartate transaminase

CKD

Chronic kidney disease

DTI

Doppler tissue imaging

ET-1

Endothelin-1

ECM

Extracellular matrix

ESRD

End-stage renal disease

ETtr

Endothelin-1 traps

FN

Fibronectin

STZ

Streptozotocin

T1D

Type 1 diabetes

Notes

Author contributions

AJ participated in the research design. The in vivo testing experiments were contracted out as stated at the beginning of the Materials and methods. AJ, AJ and VM contributed new reagents or analytic tools. AJ, VM, IJ and AJ wrote or contributed to the writing of the manuscript.

Funding

This project was privately funded.

Compliance with ethical standards

Ethics approval statement

All experiments conformed to the Guide For the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication no. 85–23, revised in 1996). Experimental protocols were reviewed and approved by the Western University council on animal care committee.

Conflict of interest

AJ, VM and AJ are members of Accelerate Cambridge, University of Cambridge, UK.

Declaration statement

Any inquiries on data of this study can be directed to Dr. Arjun Jain.

Supplementary material

40200_2019_400_MOESM1_ESM.pdf (541 kb)
ESM 1 (PDF 540 kb)

References

  1. 1.
    Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med. 2012;2(1):a007732.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Steck AK, Rewers MJ. Genetics of type 1 diabetes. Clin Chem. 2011;57(2):176–85.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Escher S, Sandholzer H. The epidemiology of type 1 diabetes mellitus. 2013;1–22.Google Scholar
  4. 4.
    Maahs DM, et al. Epidemiology of type 1 diabetes. Endocrinol Metab Clin N Am. 2010;39(3):481–97.CrossRefGoogle Scholar
  5. 5.
    Fernandes JR, et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract. 2016;117(2016):48–54.Google Scholar
  6. 6.
    Melmed S, et. al. Williams textbook of endocrinology, 2011.Google Scholar
  7. 7.
    Law B, et al. Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. Microsc Microanal. 2012;18(1):22–34.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Evans T, et al. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes. 2000;49(4):662–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Chen S, et al. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol Cell Physiol. 2003;284(2):C263–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Jain A, et al. Endothelin-1 traps potently reduce pathologic markers back to basal levels in an in vitro model of diabetes. J Diabetes Metab Disord. 2018.Google Scholar
  11. 11.
    Simonson MS, Ismail-Beigi F. Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J Biol Chem. 2011;286(13):11003–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Seligman BG, et al. Increased plasma levels of endothelin 1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2000;23(9):1395–400.CrossRefPubMedGoogle Scholar
  13. 13.
    Schneider JG, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002;15(11):967–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Stehouwer CD, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34(1):55–68.CrossRefPubMedGoogle Scholar
  15. 15.
    De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care. 2000;3(6):453–67.CrossRefPubMedGoogle Scholar
  16. 16.
    Deanfield J, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23(1):7–17.CrossRefPubMedGoogle Scholar
  17. 17.
    Bohm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res. 2007;76(1):8–18.CrossRefPubMedGoogle Scholar
  18. 18.
    He, Z. Role of PKC[delta] and Endothelin-1 in Diabetic Cardiomyopathy. In 66th Scientific Sessions 2006. American Diabetes Association.Google Scholar
  19. 19.
    Jun R, Chiming W. New sniper assignment for a celebrity-role of endothelin-1 in diabetic cardiomyopathy. Journal of Cardiothoracic - Renal Research. 2006;1(1):30–2.CrossRefGoogle Scholar
  20. 20.
    Seymour, T., What is diabetic nephropathy?, in Medical News Today. 2017.Google Scholar
  21. 21.
    A Shahriar, et al. Diabetic nephropathy, Pathophysiology and complications of diabetes mellitus; 2012.Google Scholar
  22. 22.
    Dabla PK. Renal function in diabetic nephropathy. World J Diabetes. 2010;1(2):48–56.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Georgianos PI, Agarwal R. Endothelin a receptor antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(5):338–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Chen S, et al. miR-146a regulates glucose induced upregulation of inflammatory cytokines extracellular matrix proteins in the retina and kidney in diabetes. PLoS One. 2017;12(3):e0173918.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Thomas AA, Feng B, Chakrabarti S. ANRIL regulates production of extracellular matrix proteins and vasoactive factors in diabetic complications. Am J Physiol Endocrinol Metab. 2018;314(3):E191–200.CrossRefPubMedGoogle Scholar
  26. 26.
    Feng B, et al. miR-146a mediates inflammatory changes and fibrosis in the heart in diabetes. J Mol Cell Cardiol. 2017;105:70–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Chen S, et al. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab. 2003;284(6):E1089–97.CrossRefPubMedGoogle Scholar
  28. 28.
    Wu Y, et al. ERK5 contributes to VEGF alteration in diabetic retinopathy. J Ophthalmol. 2010;2010:465824.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Roy S, et al. Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory; 1990;87(1):404–8.Google Scholar
  30. 30.
    Morrish NJ, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(Suppl 2):S14–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Lip G, Hall J. Comprehensive hypertension. ScienceDirect. 2007.Google Scholar
  32. 32.
    Mishra PK, et al. Diabetic cardiomyopathy: an Immunometabolic perspective. Front Endocrinol (Lausanne). 2017;8:72.CrossRefGoogle Scholar
  33. 33.
    Cosson S, Kevorkian JP. Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab. 2003;29(5):455–66.CrossRefPubMedGoogle Scholar
  34. 34.
    Slavica M, Biljana L. Contemporary echocardiographic techniques in early detection of diabetic cardiomyopathy. Journal of Cardiology and Current Research. 2014.Google Scholar
  35. 35.
    Townsend JC. Increased albumin excretion in diabetes. J Clin Pathol. 1990;43(1):3–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kos I, Prkačin I. Diabetic nephropathy as a cause of chronic kidney disease. Acta Med Croatica. 2014;68(4–5):375–81.PubMedGoogle Scholar
  37. 37.
    Genovese F, et al. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair. 2014;7(1):4.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Accelerate Cambridge, Judge Business SchoolUniversity of CambridgeCambridgeUK
  2. 2.National University of SingaporeSingaporeSingapore
  3. 3.Indian Institute of ManagementAhmedabadIndia

Personalised recommendations